Worcester Polytechnic Institute
IMPORTANT: All Spring 2020 in-person trainings and events at the Biomanufacturing Education & Training Center have been canceled in an effort to mitigate the impact of COVID-19. They will be rescheduled at a later date. Visit wpi.edu/news/coronavirus for the most current university updates.
5th Annual Advanced Biomanufacturing Symposium – POSTPONED
Day 1 – Advancements in Protein Therapeutics and Emerging Technologies
Day 2 – Cell and Tissue Therapies
Read the wrap up from the 2019 symposium
Sign up to receive email updates from the BETC about the symposium and other exclusive information.
Keynotes Announced!
Jochen G. Salfeld is leading the AbbVie Global Biologics Department as a Distinguished Research Fellow of the AbbVie Community of Science (ACOS) and as Vice President Global Biologics Discovery at the AbbVie Bioresearch Center (ABC) in Worcester, MA, USA.
Jochen studied in Germany, took his doctorate from Heidelberg University and completed his post-doc at the Center of Molecular Biology in Heidelberg, Germany, the Yang-Ming Medical College in Taipei, Taiwan and the Dana Farber Cancer Institute of Harvard Medical School in Boston, Massachusetts.
Jochen joined the BASF Bioresearch Corporation start-up in Cambridge, Massachusetts in 1990 – in 2001 acquired by Abbott along with BASF Pharma – and led the discovery team that collaborated with Cambridge Antibody Technology, Cambridge, UK, in the discovery of the first fully human Anti-TNF antibody D2E7, today Adalimumab (HUMIRAâ). Upon transition into development Jochen was named the first International Project Manager for D2E7 with different roles as the clinical development progressed.
In parallel he systematically expanded the team starting from a small group of scientists into a large department supporting today all Therapeutic Areas of AbbVie, including Immunology, Cancer Research, Neuroscience, Virology and beyond.
Global Biologics works on identifying the optimal therapeutics for selected therapeutic mechanisms including antibodies, multi-specifics, antibody-drug conjugates, immune-cytokines, soluble T-cell receptors and is engaged in many technology development projects.
Terence R. Flotte, MD has been the Celia and Isaac Haidak Professor, Dean of the School of Medicine and Provost and Executive Deputy Chancellor of the University of Massachusetts Medical School (UMMS) for the past 13 years. He is professor of Pediatrics and the Horae Gene Therapy Center.
An internationally known pioneer in human gene therapy, Dr. Flotte’s research has been continuously NIH funded for 26 years, and has resulted in over 250 peer-reviewed publications, which have been cited over 18,000 times. His focus is the development of recombinant viral vectors to deliver therapeutic genes and miRNA to treat diseases such as cystic fibrosis (CF) fatty acid oxidation disorders, and alpha-1 antitrypsin (AAT) deficiency. In 1995, he was Principal Investigator (PI) of the first human use of rAAV, a (CF) clinical trial, and in 2003 PI of the first rAAV intramuscular clinical trial, which began his history of Gene Therapy trials in AAT.
His awards include the 2005 Society for Pediatric Research’s E. Mead Johnson Award for Outstanding Scientific Contributions and induction into the johns Hopkins Society of Scholars in 2013. He currently serves as Editor-in-Chief of the Human Gene Therapy family of journals, and is currently serving as secretary of the board of directors of the American Society for Gene and Cell Therapy (ASGCT).
Check back for updates to the 2020 schedule.